探讨头孢哌酮钠舒巴坦钠联合喹诺酮治疗慢性阻塞性肺疾病急性加重期的临床效果

To Investigate the Clinical Effect of Cefoperazone Sulbactam Combined With Quinolones in Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

目的研究分析慢性阻肺急性加重期使用头孢哌酮钠舒巴坦钠联合喹诺酮治疗的效果。方法我院对106例慢性阻塞性肺疾病急性加重期患者进行了研究分析,将患者分成对照组和研究组,均有53例患者,两组使用常规治疗,对照组增加头孢哌酮钠舒巴坦钠治疗,研究组增加头孢哌酮钠舒巴坦钠联合喹诺酮治疗,经过1周治疗,比较分析两组治疗效果,治疗前后动脉血氧分压(PaO_2)、动脉血二氧化碳分压(PaCO_2)、不良反应等情况。结果研究组的临床治疗有效率是92.45%,对照组的临床治疗有效率是75.47%,两组结果对比,差异有统计学意义(P<0.05)。经过治疗,两组的PaO_2、PaCO_2和治疗前存在显著的改变,研究组的PaO_2高于对照组,PaCO_2低于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率5.66%,对照组不良反应发生率9.43%(P>0.05)。结论慢性阻塞性肺疾病急性加重期使用头孢哌酮钠舒巴坦钠联合喹诺酮治疗的效果突出,患者的症状缓解明显,安全性高。

Objective Analysis of acute exacerbation of chronic obstructive pulmonary disease using cefoperazone sulbactam combined with quinolone treatment effect. Methods 106 cases of acute exacerbation of chronic obstructive pulmonary disease in our hospital were studied and analyzed. The patients were divided into the control group and the study group, and there were 53 patients, two group used routine treatment, the control group increase of cefoperazone sodium and sulbactam sodium for treatment, research group of cefoperazone sulbactam combined with quinolone treatment, after 1 weeks of treatment, the therapeutic effects of the two groups were compared and analyzed. The arterial oxygen partial pressure（PaO_2）, arterial carbon dioxide partial pressure（PaCO_2） and adverse reactions before and after treatment were analyzed. Results The effective rate of clinical treatment in the study group was 92.45%, and that of the control group was 75.47%, and the difference between the two groups was statistically significant（P〈0.05）. After treatment, the two groups of PaO_2, PaCO_2 and treatment before the significant changes, the study group＇s PaO_2 was higher than the control group, PaCO_2 was lower than the control group, the difference was statistically significant（P〈0.05）. The incidence of adverse reactions in the study group was 5.66%, and that of the control group was 9.43%（P〉0.05）. Conclusion Chronic obstructive pulmonary disease with acute exacerbation of the use of cefoperazone sulbactam combined with quinolone treatment effect is prominent, patients with symptoms of high security.